Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lumena Pharmaceuticals

Shire promotes Joanne Cordeiro to chief human resources officer

But loses CFO Jeff Poulton, who is moving to Boston start-up Indigo

- PMLiVE

Shire to customise MicroHealth’s app for haemphilia patients

Will collaborate with the digital health firm on its mobile monitoring tool

Shire Basingstoke

Shire files dry eye drug lifitegrast in Europe

Analysts predict Xiidra could become a $1bn product

- PMLiVE

Shire strikes bi-specific antibody deal with Novimmune

Pharma giant obtains licence for haemophilia A candidate

- PMLiVE

Shire wins block of Roche’ ‘misinformation’ over emicizumab

Obtains a preliminary injunction from a German court

EphMRA 2017 round up

We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.

Research Partnership

- PMLiVE

Shire claims FDA approval for slow-cooked ADHD drug

Mydayis will reach the US market in the third quarter of the year

- PMLiVE

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

Lucid Group Communications Limited

- PMLiVE

Shire licences Parion dry eye drug in $535m deal

Bolsters the Irish group's ophthalmic portfolio

Shire Basingstoke

Shire finally bags EU approval for rare disease drug Natpar

Becomes first licenced treatment for hypoparathyroidism in Europe

Blending medical and digital for effective rare disease campaigns

The fundamentals of building a collaborative medical and digital team

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links